BAG3 and familial pancreatic carcinoma: It is worth noting that in two different PDAC animal models (allografts of a murine pancreatic cancer cell line in syngeneic mice and xenografts of patient‐derived PDAC in immunodeficient mice) the treatment with an anti‐BAG3 monoclonal antibody produced a strong down‐modulation of the expression of α‐SMA—an activation marker of CAFs—and a marked reduction of collagen deposition.10